regulatory approval

News

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

News

Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved for rare platelet-busting disease immune thrombocytopenia.

News

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

News

Ionis gets FDA nod for its HAE attack prophylactic treatment Dawnzera, offering less frequent dosing than its rivals.

News

Merck unit SpringWorks has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe.

News

Tonix Pharma is preparing to launch a new therapy for fibromyalgia that analysts predict could make hundreds of millions of dollars in annual sales.